© 2020


  • Aung Naing
  • Joud Hajjar

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1244)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Bettzy Stephen, Joud Hajjar
    Pages 1-36
  3. Aya A. Albittar, Omar Alhalabi, Isabella C. Glitza Oliva
    Pages 51-68
  4. Alessandro Russo, Michael G. McCusker, Katherine A. Scilla, Katherine E. Arensmeyer, Ranee Mehra, Vincenzo Adamo et al.
    Pages 69-92
  5. Jonathan Mizrahi, Shubham Pant
    Pages 93-106
  6. Omar Alhalabi, Hind Rafei, Mehmet Asim Bilen, Amishi Yogesh Shah
    Pages 107-147
  7. Jeffrey How, Ami Patel, Amir Jazaeri
    Pages 149-182
  8. Nazanin Majd, Pushan Dasgupta, John de Groot
    Pages 183-203
  9. Lauren E. Colbert, Anuja Jhingran
    Pages 205-213
  10. Ranjit Nair, Jason Westin
    Pages 215-233
  11. Anisha B. Patel, Omar Pacha
    Pages 235-246
  12. Hamzah Abu-Sbeih, Yinghong Wang
    Pages 247-253
  13. Linda Zhong, Mehmet Altan, Vickie R. Shannon, Ajay Sheshadri
    Pages 255-269
  14. Hamzah Abu-Sbeih, Yinghong Wang
    Pages 271-276
  15. Abdulrazzak Zarifa, Juan Lopez-Mattei, Nicolas Palaskas, Cezar Iliescu, Jean-Bernard Durand, Peter Y. Kim
    Pages 277-285
  16. Maen Abdelrahim, Ala Abudayyeh
    Pages 287-293
  17. Akanksha Srivastava, Nagham Al-Zubidi, Eric Appelbaum, Dan S. Gombos, Marc-Elie Nader, Paul W. Gidley et al.
    Pages 295-307
  18. Mira Ayoub, Yousra Eleneen, Rivka R. Colen
    Pages 309-324
  19. Joseph Toker, Reetakshi Arora, Jennifer A. Wargo
    Pages 325-334

About this book


Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches.  Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions.

The  book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.


translational cancer immunology vaccine il-10 immune-oncology tumor immunology immune-therapy immune checkpoint inhibitors radiation cardiotoxicity

Editors and affiliations

  • Aung Naing
    • 1
  • Joud Hajjar
    • 2
  1. 1.MD Anderson Cancer CenterUniversity of TexasHoustonUSA
  2. 2.Baylor College of MedicineTexas Children’s HospitalHoustonUSA

About the editors

Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing’s research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.

Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.

Bibliographic information

  • Book Title Immunotherapy
  • Editors Aung Naing
    Joud Hajjar
  • Series Title Advances in Experimental Medicine and Biology
  • Series Abbreviated Title Adv Exp Med Biol
  • DOI
  • Copyright Information Springer Nature Switzerland AG 2020
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-030-41007-0
  • eBook ISBN 978-3-030-41008-7
  • Series ISSN 0065-2598
  • Series E-ISSN 2214-8019
  • Edition Number 3
  • Number of Pages XII, 339
  • Number of Illustrations 9 b/w illustrations, 35 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods


“The optimal audience for this book should be clinical oncologists. The book has a difficult time striking the right balance of including important details versus brevity to be useful for most readers.” (Matthew Gumbleton, Doody’s Book Reviews, August 21, 2020)